

Chambersburg/Waynesboro Hospitals Antibioqram 2022 - Blood

Antibiogram represents organisms isolated from Jan to Dec 2022 and was prepared by members of the Depart
Microbiology and Pharmacy

| (%) Susceptibility Color Key: Green: ≥85% Yellow: 70-84% Red: <70% *Based on CLSI recommendations only organisms with at least 30 isolates are reported. Less than 30 isolates tested therefore results must be interpreted with caution for those organisms Susceptibility for additional organisms can be obtained from the Microbiology Department. | Gram Negative | | Gram Positive | | | |
|--|------------------|-----------------------|-----------------------|-----------|-----------|---------------------------------------|
| | Escherichia coli | Klebsiella pneumoniae | Enterococcus faecalis | MRSA | MSSA | Staphylococcus sp. Coagulase Negative |
| Isolates | 190 | 52 | 37 | 38 | 83 | 43 |
| Amikacin | 100 | 98 | | | | |
| Amoxicillin/Clavulanate | 82 | 90 | | | 100 | 51 |
| Ampicillin | 60 | | 100 | | | |
| Ampicillin/Sulbactam | 69 | 88 | | | 100 | 51 |
| Aztreonam | 92 | 92 | | | | |
| Cefazolin | 78 | 90 | | | 100 | 51 |
| Cefepime | 92 | 92 | | | 100 | 51 |
| Ceftaroline | | | | 100 | 100 | |
| Ceftazidime | 91 | 92 | | | | |
| Ceftazidime/Avibactam | 100 | 100 | | | | |
| Ceftriaxone | 90 | 92 | | | 100 | 51 |
| Cefuroxime | 89 | 88 | | | | |
| Ciprofloxacin | 80 | 88 | 64 | | 89 | 65 |
| Clindamycin | | | | 40 | 78 | 76 |
| Daptomycin | | | 100 | 100 | 100 | 100 |
| Ertapenem | 99 | 100 | | | | |
| Gentamicin | 93 | 98 | | | | |
| Imipenem | 100 | 100 | | | 100 | 51 |
| Levofloxacin | 86 | 94 | 72 | 15 | 91 | 67 |
| Linezolid | | | 100 | 100 | 100 | 100 |
| Meropenem | 100 | 100 | | | 100 | 51 |
| Meropenem/Vaborbactam | 100 | 100 | | | | |
| Oxacillin | | | | | 100 | 51 |
| Piperacillin/Tazobactam | 91 | 90 | | | 100 | |
| Tobramycin | 93 | 98 | | | | |
| TMP/SMX | 86 | 96 | | 100 | 100 | 72 |
| Vancomycin | | | 94 | 100 | 100 | 100 |

Antimicrobial susceptibility testing performed according to the guidelines set forth in: (1) Clinical Laboratory Standar

Institute (CLSI). Performance standards for antimicrobial disk susceptibility tests; approved standard-thirteenth addit A13, Vol. 38, No. 1, April 2019; (2) CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-eleventh edition. M7-A11, Vol. 38, No. 2, April 2019; and (3) CLSI. Performance Standards for Antimicrobial Susceptibility Testing; 32nd edition Informational Supplement. M100-S32, February 2022.

ments of

| |
|------------------------------------|
| |
| Streptococcus agalactiae (Group B) |
| 26* |
| |
| 100 |
| |
| |
| 100 |
| |
| |
| 100 |
| |
| |
| 38 |
| 100 |
| |
| |
| 100 |
| 100 |
| |
| |
| |
| |
| 100 |

ds

tion. M2-
dards for